Search - tctmd.com

Displaying 101 - 120 of 168

Presentation TCT 2013

Point-of-Care Genetic Testing of Eleven CYP2C19 Single Nucleotide Polymorphisms Identifies Extensive and Reduced Metabolizers of Clopidogrel With High Accuracy in Patients With...

Presenter: David Erlinge, Stefan James, Suman Duvvuru, Joseph Jakubowski, Henrik Wanger, Christoph Varenhorst, Udaya Tantry, Patricia Brown, David Small, Brian Moser, Scott Sundseth, Joseph Walker, Kenneth Winters, Paul Gurbel

January 31, 2013

Presentation TCT 2013

Platelet Function Testing Predicts Bleeding In Patients Exposed To Clopidogrel Undergoing Coronary Artery Bypass Grafting

Presenter: Grant Reed, Elaine Hoffman, Amit Kumar, Andrew Maree, Dalton McLean, Jacki Buros, Sary Aranki, Prem Shekar, Arvind Agnihotri, Laura Williams, Kenneth Rosenfeld, Christopher Cannon

January 31, 2013

Presentation TCT 2013

Paraoxonase 1 Gene Polymorphism Does Not Affect Clopidogrel Response Variability But Is Associated with Clinical Outcome After Percutaneous Coronary Intervention

Presenter: Jin Joo Park, Kyung Woo Park, Jeehoon Kang, Ki-Hyun Jeon, Si-Hyuck Kang, Jung-Kyu Han, Sang Eun Lee, Han-Mo Yang, Hae-Young Lee, Hyun-Jae Kang, Bon-Kwon Koo, Byung-Hee Oh, Young-Bae Park, Hyo-Soo Kim

January 31, 2013

Presentation TCT 2013

P2Y12 Reactivity units (PRU) to Predict Hyporesponsiveness to Clopidogrel in Patients with Chest Pain with Prior History of Coronary Artery Stenting in Emergency Department

Presenter: Rakesh Sharma, Stephen Erickson, Rohit Sharma, Hanumanth Reddy, Donald Voelker, Harvinder Dod, Vibhuti Singh, james Marsh

January 31, 2013

Presentation TCT 2013

Meta-analysis Comparing Bleeding Rates After Low Versus High Dose Clopidogrel In Patients Undergoing Percutaneous Coronary Intervention And Receiving A Glycoprotein IIb/IIIa...

Presenter: Christopher Huff, Shikhar Agarwal, James Lai, Clay Cauthen, A. Michael Lincoff, Leslie Cho

January 31, 2013

Presentation TCT 2013

Markedly Reduced Platelet Inhibition with Clopidogrel Given To Patients Undergoing Therapeutic Hypothermia Post Cardiac Arrest

Presenter: Rohit Moudgil, Haytham Al-Turbak, Michel Le May, George Wells, Derek So, Alexander Dick, Michael Froeschl, Christopher Glover, Jean-Francois Marquis, Marino Labinaz

January 31, 2013

Presentation TCT 2013

Discontinuation of Long-Term Clopidogrel Therapy is Associated with Death and Myocardial Infarction after Saphenous Vein Graft Percutaneous Coronary Intervention

Presenter: Amit Sachdeva, Sumati Bavisetty, Gerald Beckham, Albert Shen, Vicken Aharonian, Prakash Mansukhani, Gregg Stone, Martin Leon, Jeffrey Moses, Naing Moore, Ric Hyett, Richard Contreras, Somjot Brar

January 31, 2013

Presentation TCT 2013

Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-Eluting Stents: Insight From the Florence Left Main-PCI Registry

Presenter: Renato Valenti, Angela Migliorini, Guido Parodi, Ruben Vergara, Nazario Carrabba, Emilio Vincenzo Dovellini, David Antoniucci

January 31, 2013

Presentation

Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms, Noncompliance, Diet, Smoking, Co-medications, and Preexistent Variability in Platelet Func

Presenter: Andrew L. Frelinger

January 15, 2013

Presentation

Safety of Reloading Prasugrel in Addition to Clopidogrel Loading in ACS Patients Undergoing PCI

Presenter: J.P. Loh

January 09, 2013

Presentation

Reduction in First and Recurrent Cardiovascular Events with Ticagrelor vs. Clopidogrel

Presenter: P. Kohli

January 06, 2013

Presentation

Association of Clopidogrel Pretreatment with Mortality, CV Events, and Major Bleeding After PCI

Presenter: A. Bellemain-Appaix

December 17, 2012

Presentation

Bioequivalence in the Real World Is a Complex Challenge: The Case of Clopidogrel

Presenter: Rossella Marcucci

December 12, 2012

Presentation

Evaluating the Impact of Public Health Notification: Duke Clopidogrel Experience

Presenter: Eric L. Eisenstein

November 19, 2012

Presentation

Discontinuation of Long-term Clopidogrel Therapy Is Associated with Death and MI After SVG PCI

Presenter: A. Sachdeva

November 13, 2012

Presentation TCT 2012

Debate: Clopidogrel is Enough and Still Plays a Role for Most!

Presenter: Michael Love

October 25, 2012

Presentation TCT 2012

ADAPT-DES One Year: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel and Aspirin Hyporesponsiveness on Patient Outcomes

Presenter: Gregg Stone

October 25, 2012

Presentation TCT 2012

Clopidogrel Is Still the Choice for Most!

Presenter: Shamir Mehta

October 24, 2012

Presentation TCT 2012

TRILOGY ACS Angiographic Cohort: A Prospective, Randomized Trial of Prasugrel vs. Clopidogrel in Patients with Non-ST-Segment Elevation ACS Who Are Medically Managed After...

Presenter: Stephen Wiviott

October 24, 2012

Presentation TCT 2012

TCT-54. The Influence of Smoking Status on the Pharmacodynamics of Prasugrel and Clopidogrel: The PARADOX Study

Presenter: Paul Gurbel

October 23, 2012

Advertisement

Point-of-Care Genetic Testing of Eleven CYP2C19 Single Nucleotide Polymorphisms Identifies Extensive and Reduced Metabolizers of Clopidogrel With High Accuracy in Patients With...

Platelet Function Testing Predicts Bleeding In Patients Exposed To Clopidogrel Undergoing Coronary Artery Bypass Grafting

Paraoxonase 1 Gene Polymorphism Does Not Affect Clopidogrel Response Variability But Is Associated with Clinical Outcome After Percutaneous Coronary Intervention

P2Y12 Reactivity units (PRU) to Predict Hyporesponsiveness to Clopidogrel in Patients with Chest Pain with Prior History of Coronary Artery Stenting in Emergency Department

Meta-analysis Comparing Bleeding Rates After Low Versus High Dose Clopidogrel In Patients Undergoing Percutaneous Coronary Intervention And Receiving A Glycoprotein IIb/IIIa...

Markedly Reduced Platelet Inhibition with Clopidogrel Given To Patients Undergoing Therapeutic Hypothermia Post Cardiac Arrest

Discontinuation of Long-Term Clopidogrel Therapy is Associated with Death and Myocardial Infarction after Saphenous Vein Graft Percutaneous Coronary Intervention

Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-Eluting Stents: Insight From the Florence Left Main-PCI Registry

Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms, Noncompliance, Diet, Smoking, Co-medications, and Preexistent Variability in Platelet Func

Safety of Reloading Prasugrel in Addition to Clopidogrel Loading in ACS Patients Undergoing PCI

Reduction in First and Recurrent Cardiovascular Events with Ticagrelor vs. Clopidogrel

Association of Clopidogrel Pretreatment with Mortality, CV Events, and Major Bleeding After PCI

Bioequivalence in the Real World Is a Complex Challenge: The Case of Clopidogrel

Evaluating the Impact of Public Health Notification: Duke Clopidogrel Experience

Discontinuation of Long-term Clopidogrel Therapy Is Associated with Death and MI After SVG PCI

Debate: Clopidogrel is Enough and Still Plays a Role for Most!

ADAPT-DES One Year: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel and Aspirin Hyporesponsiveness on Patient Outcomes

Clopidogrel Is Still the Choice for Most!

TRILOGY ACS Angiographic Cohort: A Prospective, Randomized Trial of Prasugrel vs. Clopidogrel in Patients with Non-ST-Segment Elevation ACS Who Are Medically Managed After...

TCT-54. The Influence of Smoking Status on the Pharmacodynamics of Prasugrel and Clopidogrel: The PARADOX Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content